CD274 and non-small cell lung carcinoma: One study has presented the outcome analysis depending on concomitant drugs at baseline in a large cohort of patients with metastatic NSCLC (PD-L1 expression ≥ 50%) undergoing first-line monotherapy with pembrolizumab; patients undergoing chemotherapy represented the control cohort [68].